argenex (NASDAQ:ARGX) Releases Quarterly Earnings Results, Beats Estimates By $1.97 EPS

argenex (NASDAQ:ARGX) released its quarterly earnings results on Thursday. The company reported $8.02 EPS for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97, Zacks reports. argenex had a net margin of 41.58% and a return on equity of 29.78%.

Here are the key takeaways from argenex’s conference call:

• argenx reported positive Phase 3 ADAPT OCULUS results in ocular MG—VYVGART high‑titer met the primary endpoint (p=0.012; mean MG‑II improvement 4.04 vs 1.99) with no new safety signals, and the company plans to file an sBLA.
• Backed by recent seronegative data and a PDUFA date on May 10, management expects to expand VYVGART’s label toward the broadest MG indication, targeting an addressable U.S. population of roughly 60,000 patients.
• Financials were strong—Q4 product sales of $1.3B and full‑year $4.2B (90% YoY growth), first annual operating profit of $1.1B, and ~$4.4B cash at year‑end, which management says funds continued commercial and pipeline investment.
• Commercial momentum continues with ~19,000 patients on VYVGART globally, the prefilled syringe (PFS) launch driving uptake and >4,700 prescribers, and expanded PFS access (UnitedHealthcare) covering >90% of lives to aid adoption in MG and CIDP.
• The pipeline is broadening (next‑gen FcRn assets ARGX‑213/ARGX‑124, empasiprubart MMN readout in Q4, myositis Phase‑3 programs), but management expects higher R&D and SG&A spending in 2026—continued investment with timing and commercial impact still uncertain.

argenex Price Performance

Shares of ARGX traded down $45.42 during mid-day trading on Thursday, reaching $771.53. The company had a trading volume of 829,992 shares, compared to its average volume of 394,104. The company’s 50-day moving average is $829.64 and its 200-day moving average is $810.13. argenex has a twelve month low of $510.05 and a twelve month high of $934.62. The company has a market capitalization of $47.74 billion, a P/E ratio of 33.13, a P/E/G ratio of 0.73 and a beta of 0.37.

Institutional Investors Weigh In On argenex

A number of large investors have recently bought and sold shares of the business. Wellington Management Group LLP raised its stake in shares of argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the last quarter. Morgan Stanley lifted its stake in argenex by 19.2% in the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after buying an additional 83,746 shares during the period. Invesco Ltd. grew its holdings in argenex by 390.4% during the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after purchasing an additional 331,489 shares during the period. Bank of America Corp DE increased its position in shares of argenex by 1.9% in the 3rd quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock valued at $252,525,000 after buying an additional 6,259 shares in the last quarter. Finally, Two Sigma Investments LP increased its holdings in shares of argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after acquiring an additional 250,278 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 result: argenx reported topline positive ADAPT OCULUS data for VYVGART in ocular myasthenia gravis (primary endpoint met, p=0.012), supporting a planned sBLA to the FDA to expand the label into oMG. Argenx Touts Positive Phase 3 Eye Disease Study Results
• Positive Sentiment: Strong sales and FY results: argenx announced $1.3B Q4 and $4.2B FY 2025 product net sales (≈90% YoY growth) — evidence of rapid commercial traction for VYVGART. Full Year 2025 Financial Results
• Positive Sentiment: Quarterly beat: ARGX reported $8.02 EPS for the quarter vs. $6.05 consensus, with strong margins and ROE — a near-term fundamental beat that underpins revenue strength. Conference call and slide deck available for details. Earnings Release & Call Materials
• Neutral Sentiment: Analyst notes and previews: several earnings previews and insights were published ahead of/with results — useful for forward‑looking assumptions but do not change the headline clinical and sales news. Earnings Insights
• Negative Sentiment: Heavy trading and profit‑taking pressure: intraday volume is well above average and the stock is trading lower — likely a sell-the-news response after a large run and the strong prints. Market is also digesting valuation (large market cap, elevated multiples) versus near-term visibility on incremental label expansion and global uptake. Market Data
• Negative Sentiment: Short‑interest data appears unreliable in some reports (zero/NaN entries) — but elevated volatility and higher volume can attract short sellers or traders, adding near‑term pressure. Monitor confirmed short interest updates. What To Expect From Q4 2025

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Stifel Nicolaus boosted their target price on argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Robert W. Baird lowered shares of argenex from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 18th. DZ Bank upgraded shares of argenex to a “strong-buy” rating in a report on Friday, December 19th. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Finally, Royal Bank Of Canada boosted their price target on argenex from $860.00 to $925.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $986.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.